after you join the study you will be randomly assigned to one of two treatment groups. one group receives a combination of atezolizumab plus either lenvatinib or sorafenib. the other group receives only lenvatinib or only sorafenib.

before any medication is given you will undergo baseline tests. these may include blood tests, imaging scans, and measurements of vital signs to document the current status of your liver cancer.

once randomization is complete you will begin the study medication(s).

atezolizumab is supplied as a 1200 mg solution for infusion and is given by iv infusion (through a vein).

lenvatinib is supplied as a 12 mg hard capsule taken by mouth.

sorafenib is supplied as an 800 mg film‑coated tablet taken by mouth.

the exact frequency and duration of each medication are defined by the study protocol and will be followed throughout the trial.

you will continue to receive the assigned medication(s) according to the schedule set by the protocol. treatment continues until disease progression, unacceptable side effects, or the end of the study period.

regular clinic visits are scheduled to monitor your health. during these visits blood samples, vital‑sign checks, and quality‑of‑life questionnaires may be collected. imaging studies may be performed to assess the status of the cancer.

if the cancer progresses or side effects become unacceptable, the study medication(s) will be stopped.

after treatment ends you may continue to have follow‑up visits. these visits collect information about overall survival and any long‑term effects.